there are no studies in the literature about the effectiveness of adalimumab biosimilar ABP 501 in Crohn's disease. The aim of this study was to evaluate its effectiveness and safety.
Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study
Ribaldone, Davide Giuseppe
First
;Caviglia, Gian Paolo;Pellicano, Rinaldo;Vernero, Marta;Saracco, Giorgio Maria;Morino, Mario;
2020-01-01
Abstract
there are no studies in the literature about the effectiveness of adalimumab biosimilar ABP 501 in Crohn's disease. The aim of this study was to evaluate its effectiveness and safety.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
07_OR_6693_ing_copia.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
594.87 kB
Formato
Adobe PDF
|
594.87 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
